All Outputs (33)

The prognostic significance of ALDH1A1 expression in early invasive breast cancer (2020)
Journal Article

Aims: Aldehyde dehydrogenase family 1 member A1 (ALDH1A1)is reportedly a key ALDH isozyme linked to the cancer stem cells (CSC) of many solid tumours, where it is involved in self-renewal, differentiation and self-protection. In this study, the progn... Read More about The prognostic significance of ALDH1A1 expression in early invasive breast cancer.

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer (2020)
Journal Article

Background: Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identifying factors associated with the progression of early stage BC can help understand the risk of metastasis and guide treatment dec... Read More about Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.

SPAG5: An Emerging Oncogene (2020)
Journal Article

SPAG5 is a mitotic spindle protein. Recent studies have found that it is overexpressed in many human cancers and functions as an oncogene. We summarize the current underlying mechanisms for its oncogenic roles in regulating cellular behaviors of canc... Read More about SPAG5: An Emerging Oncogene.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer (2020)
Journal Article

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequenc... Read More about The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age (2020)
Journal Article

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Multi-cohort analysis demonstrated that cytoplasmic cyclin E expression in primary breast tumors predicts aggressive disease. However, compared to their younger counterparts, older patients ha... Read More about Cytoplasmic cyclin E is an independent marker of aggressive tumor biology and breast cancer-specific mortality in women over 70 years of age.

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ (2020)
Journal Article

Background The role of different subtypes of tumour infiltrating lymphocytes (TILs) in breast ductal carcinoma in situ (DCIS) is still poorly defined. This study aimed to assess the prognostic significance of B and T lymphocytes and immune checkpo... Read More about The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.

The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma (2020)
Journal Article

Intra-ductal papillomas (IDP) are challenging breast findings because of their variable risk of progression to malignancy. The molecular events driving IDP development and genomic features of malignant progression are poorly understood. In this study... Read More about The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.

PIK3C? expression by fibroblasts promotes triple-negative breast cancer progression (2020)
Journal Article

As there is growing evidence for the tumor microenvironment’s (TME) role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple negative breast cancer (TNBC). Using a high-throughput kinome screen combined with 3D invasi... Read More about PIK3C? expression by fibroblasts promotes triple-negative breast cancer progression.

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers (2020)
Journal Article

© 2020, The Author(s). Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) have been investigated as triple-negative breast cancer (TNBC) biomarkers. Reduced EGFR levels can be compensated by increases in HER3;... Read More about Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib (2020)
Journal Article

Background: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, th... Read More about XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.

A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ (2020)
Journal Article

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer (2020)
Journal Article

The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer prognostication in clinically relevant subgroups of patients. The TSR was assessed on hematoxylin and eosin stained tissue slides of 1794 breast cancer patients fro... Read More about The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer.